Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 604,867
  • Shares Outstanding, K 54,151
  • Annual Sales, $ 0 K
  • Annual Income, $ -230,700 K
  • 60-Month Beta 2.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.30
  • Number of Estimates 5
  • High Estimate -1.28
  • Low Estimate -1.32
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +25.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.18 +12.77%
on 02/27/20
15.53 -26.08%
on 02/05/20
-2.17 (-15.90%)
since 01/27/20
3-Month
10.18 +12.77%
on 02/27/20
17.94 -36.01%
on 01/09/20
-2.54 (-18.12%)
since 11/27/19
52-Week
10.18 +12.77%
on 02/27/20
41.93 -72.62%
on 04/05/19
-24.72 (-68.29%)
since 02/27/19

Most Recent Stories

More News
Atara Biotherapeutics: 4Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $78.5 million in its fourth quarter.

ATRA : 11.48 (+2.78%)
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 11.48 (+2.78%)
Atara Biotherapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27,...

ATRA : 11.48 (+2.78%)
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 11.48 (+2.78%)
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 11.48 (+2.78%)
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 11.48 (+2.78%)
Epizyme Inc has the Best Relative Performance in the Biotechnology Industry (EPZM , BPMC , ATRA , HALO , TGTX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ATRA : 11.48 (+2.78%)
BPMC : 54.38 (-5.52%)
EPZM : 20.47 (-5.41%)
Relatively Good Performance Detected in Shares of Novavax Inc in the Biotechnology Industry (NVAX , ATRA , LJPC , ESPR , ARWR)

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ATRA : 11.48 (+2.78%)
LJPC : 6.73 (-2.89%)
NVAX : 11.80 (+27.98%)
ARWR : 36.00 (-0.17%)
Alkermes Plc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (ALKS , CLVS , ATRA , FOLD , SGEN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 19.63 (-3.11%)
ATRA : 11.48 (+2.78%)
CLVS : 6.84 (-8.49%)
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...

ATRA : 11.48 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ATRA with:

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

2nd Resistance Point 12.96
1st Resistance Point 12.22
Last Price 11.48
1st Support Level 10.46
2nd Support Level 9.44

See More

52-Week High 41.93
Fibonacci 61.8% 29.80
Fibonacci 50% 26.06
Fibonacci 38.2% 22.31
Last Price 11.48
52-Week Low 10.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar